Aims: Parkinson’s disease (PD) affects 1–3% of the population aged over 65. Stress seems to contribute to
PD neuropathology, probably by dysregulation of the hypothalamic–pituitary–adrenal axis. Key factors are
oxidative stress, mitochondrial dysfunction and neuronal glucocorticoid-induced toxicity. Insulin-like growth
factor II (IGF-II) has shown antioxidant and neuroprotective effects in some neurodegenerative disorders.
Therefore, our aim was to study IGF-II protective effects against oxidative damage on a cellular combined
model of PD and mild to moderate stress, based on corticosterone (CORT) and the dopaminergic
neurotoxin 1-methyl-4-phenylpyridinium (MPP+).
Methods: The dopaminergic neuronal cell line SN4741 (RRID:CVCL_S466) derived from mouse substantia
nigra were exposed to 200 μM MPP+, 0.5 μM CORT or both, with or without 25 ng/mL IGF-II, for 2.5 or 6 h.
Cell viability, oxidative stress parameters, mitochondrial and dopamine markers and intracellular signaling
pathways were evaluated.
Results: The administration of MPP+ or CORT individually led to cell damage compared to control
situations, whereas the combination of both drugs produced very considerable toxic synergistic effect. IGF-II
counteracts the mitochondrial-oxidative damage, protecting dopaminergic neurons from death and
neurodegeneration. IGF-II promotes PKC activation and nuclear factor (erythroid-derived 2)-like 2
antioxidant response in a glucocorticoid receptor-dependent pathway, preventing oxidative cell damage
and maintaining mitochondrial function.
Conclusions: IGF-II capacity to protect nigral dopamine neurons against mitochondrial-oxidative damage
induced by CORT and MPP+ was demonstrated. Thus, IGF-II is a potential therapeutic tool for prevention
and treatment of PD patients suffering mild to moderate emotional stress.